# To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

> **NCT02823171** · PHASE1 · COMPLETED · sponsor: **CTI BioPharma** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Treatment A: 400 mg Pacritinib P3CT
- **DRUG:** Treatment B: 400 mg of pacritinib FMI

## Key facts

- **NCT ID:** NCT02823171
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02823171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02823171, "To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02823171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*